Real-world study of apatinib in the treatment of gynecological malignancies

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040225

Enrollment

Unknown

Registered

2020-11-25

Start date

2020-11-30

Completion date

Unknown

Last updated

2021-02-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gynecological Malignancies

Interventions

Case series:Nil

Eligibility

Sex/Gender

Female

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years old; 2. Patients with gynecological malignant tumors diagnosed by pathology or histology; 3. Volunteer to join this study and sign an informed consent form; Researchers believe that it can benefit.

Exclusion criteria

Exclusion criteria: 1. Those who have been confirmed to be allergic to apatinib mesylate tablets and/or its excipients; 2. Pregnant or breastfeeding women; 3. Except for patients with contraindications to apatinib; 4. The doctor thinks it is not suitable for inclusion.

Design outcomes

Primary

Measure	Time frame
Progression-free survival;	—

Countries

China

Contacts

Public ContactHuirong Shi

First Affiliated Hospital of Zhengzhou University

hrshi2011@163.com+86 13838342569

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026